© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
October 17, 2020
Neurology News Network for the week ending October 17, 2020.
October 14, 2020
If approved, rimegepant will be the first and only anti-CGRP agent indicated for both the preventive and acute treatment of migraine.
August 29, 2020
Neurology News Network for the week ending August 29, 2020.
August 22, 2020
The data support and extend the safe use of combination treatment with rimegepant and CGRP monoclonal antibodies in migraine that was initially reported in 2 earlier cases.
May 02, 2020
Neurology News Network for the week ending May 2.
April 24, 2020
Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.
April 18, 2020
Neurology News Network for the week ending April 18, 2020.
April 15, 2020
The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.
April 14, 2020
Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.
April 04, 2020
Neurology News Network for the week ending April 4, 2020.